ABSTRACT
The number of corona virus cases is steeply increasing day by day worldwide. According to WHO, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection is managed by preventing infection, detection of cases, providing supportive care, and monitoring. No specific options (antiviral, monoclonal antibody or vaccine) are available for controlling and treatment of the COVID-19 infection, Convalescent plasma (CP) therapy becomes the first available option to treat this pandemic situation according to the successful use of plasma therapy in a historical corona virus outbreak. Plasma obtained from COVID-19 recovered patients is used as prophylaxis therapy or as a therapeutic option. Plasma collection, preparation, and administration requires a proper procedure to enhance its productivity. Preparation of plasma with adequate neutralizing antibody titer becomes challenging. CP therapy may provide antiviral and immunomodulatory effect to SARS-CoV-2 infected patients by controlling overactive immune system such as cytokine storm, Th1/Th17 ratio, and hypercoagulable state. Based on the available case studies data, the administration of CP is proven to be beneficial in treating critically ill patients of SARS-CoV-2 infection. Passive antibody transfusion may reduce viral load with no severe adverse reaction and provide passive immunity against the virus. However, further well-designed clinical trials are needed to establish true clinical efficacy and safety of plasma therapy.